Clinical Management and Key Considerations to Target Optimal Treatment of Inflammatory Bowel Disease

Clinical Management and Key Considerations to Target Optimal Treatment of Inflammatory Bowel Disease is organized by National Association of Managed Care Physicians (NAMCP).,,This activity is valid from June 1, 2022, to August 1, 2023,,Description:,Inflammatory bowel disease (IBD) is a chronic, frequently progressive condition that affects approximately 1.6 million people in the United States. This lifelong, systemic autoimmune illness often strikes patients at a young age and must be managed across a lifetime. According to the Crohn’s and Colitis Foundation of America, there are as many as 70,000 new cases diagnosed in a year. The diagnosis of IBD is most commonly based on imaging to assess the portions of the small bowel that are inaccessible to optical endoscopic visualization, which may also include a combination of endoscopy and histopathology. Imaging plays a critical role in the initial diagnosis and ongoing evaluation of IBD patients.,,Upon completion of this activity, participants will be able to:,• Review guidelines on management and treatment of inflammatory bowel disease (IBD),• Describe new diagnostic methods for IBD patients,• Analyze recent clinical trial data regarding the next generation of therapies, including S1P therapies and JAK inhibitors, in IBD management,• Explore the current and emerging therapies by looking at their safety, efficacy, and mechanisms of action, with a close look at the impact of biosimilars,• Identify treatment challenges and adverse events in patients with IBD,• Discuss the role of the multidisciplinary team in improving patient outcomes for IBD.